Tylenol 3®
Acetaminophen 300 mg / Codeine 30 mg · oral tablet
Analgesics
Approved uses
Mild to moderate pain where an opioid is appropriate and alternative treatments are inadequate
1 to 2 tablets (codeine 30 mg / acetaminophen 300 mg) every 4 hours as needed; maximum in 24 hours is codeine 360 mg and acetaminophen 4,000 mg
Watch total acetaminophen if the patient is also taking an over-the-counter product containing it
Contraindications
- All children younger than 12 years
- Postoperative management in children younger than 18 years after tonsillectomy or adenoidectomy
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Concurrent use of monoamine oxidase inhibitors (MAOIs), or use of MAOIs within the last 14 days
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity, such as anaphylaxis, to codeine, acetaminophen or any of the ingredients
Acetaminophen 300 mg with codeine phosphate 30 mg tablets, supplied in bottles of 6
Codeine is an opioid agonist relatively selective for the mu-opioid receptor, but with a much weaker affinity than morphine. The analgesic properties of codeine have been speculated to come from its conversion to morphine, although the exact mechanism of analgesic action remains unknown. The precise mechanism of the analgesic properties of acetaminophen is not established but is thought to involve central actions.
Warnings & Precautions
- Addiction, Abuse, and Misuse: Exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Addiction can occur at recommended dosages. Assess each patient's risk prior to prescribing, and monitor all patients regularly for the development of these behaviors and conditions.
- Opioid Analgesic REMS: FDA has required a REMS for these products. Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal.
- Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. The risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy and following dosage increases.
- Sleep-Related Breathing Disorders: Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage.
- Accidental Ingestion: Accidental ingestion, especially by children, can result in a fatal overdose.
- Patient Access to Naloxone: Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver, both when initiating and renewing treatment. Consider prescribing naloxone based on the patient's risk factors for overdose, or if household members (including children) or other close contacts are at risk for accidental ingestion or overdose.
- Life-Threatening Respiratory Depression in Children: Life-threatening respiratory depression and death have occurred in children who received codeine, most often following tonsillectomy and/or adenoidectomy, and many had evidence of being ultra-rapid metabolizers. Contraindicated in children younger than 12 years and in children younger than 18 years following tonsillectomy and/or adenoidectomy.
- Life-Threatening Respiratory Depression in Adolescents: Avoid use in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as post-operative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression.
- Respiratory Depression in Ultra-Rapid Metabolizers: Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype. They convert codeine into morphine more rapidly and completely, and even at labeled dosage regimens may have life-threatening or fatal respiratory depression. Individuals who are ultra-rapid metabolizers should not use this product.
- Death in a Nursing Infant: At least one death was reported in a nursing infant who was exposed to high levels of morphine in breast milk because the mother was an ultra-rapid metabolizer of codeine. Breastfeeding is not recommended during treatment.
- Neonatal Opioid Withdrawal Syndrome: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. Advise pregnant women using opioids for a prolonged period of the risk and ensure that appropriate treatment will be available.
- Opioid Toxicity and Opioid Withdrawal: CYP3A4 inhibitors, stopping a CYP3A4 inducer, or stopping a CYP2D6 inhibitor may raise morphine levels and may cause potentially fatal respiratory depression. CYP3A4 inducers, stopping a CYP3A4 inhibitor, or adding a CYP2D6 inhibitor may lower morphine levels, with reduced efficacy or, in some patients, opioid withdrawal. Follow patients for signs and symptoms that may reflect opioid toxicity and opioid withdrawal, and consider dosage adjustment.
- Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most cases of liver injury are associated with doses above 4,000 milligrams per day, and often involve more than one acetaminophen-containing product. The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. Instruct patients not to use more than one product that contains acetaminophen.
- Profound Sedation, Respiratory Depression, Coma, and Death: Concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate, limit dosages and durations to the minimum required, and follow patients for respiratory depression and sedation.
- Decreased Respiratory Drive Including Apnea: Patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with substantially compromised respiratory function, hypoxia, hypercapnia, or pre-existing respiratory depression, are at increased risk of decreased respiratory drive including apnea, even at recommended dosages.
- Respiratory Depression in Elderly or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients. Monitor such patients closely, particularly when initiating and titrating the dosage and when the drug is given concomitantly with other drugs that depress respiration. Alternatively, consider non-opioid analgesics.
- Respiratory Depression, Coma, and Confusion: MAOIs may potentiate the effects of morphine, codeine's active metabolite, including respiratory depression, coma, and confusion. This product should not be used in patients taking MAOIs or within 14 days of stopping such treatment.
- Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than 1 month of use. If suspected, confirm the diagnosis with diagnostic testing as soon as possible. If diagnosed, treat with physiologic replacement doses of corticosteroids and wean the patient off of the opioid.
- Severe Hypotension: May cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients, with increased risk in patients with reduced blood volume or on certain CNS depressant drugs. Monitor for signs of hypotension after initiating or titrating the dosage. Avoid use in patients with circulatory shock.
- Serious Skin Reactions: Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Discontinue at the first appearance of skin rash or any other sign of hypersensitivity.
- Increased Intracranial Pressure: In patients who may be susceptible to the intracranial effects of carbon dioxide retention, such as those with increased intracranial pressure or brain tumors, it may reduce respiratory drive, and the retention can further increase intracranial pressure. Monitor for sedation and respiratory depression, particularly when initiating therapy. Opioids may also obscure the clinical course in a patient with a head injury. Avoid use in patients with impaired consciousness or coma.
- Hypersensitivity/Anaphylaxis: There have been post-marketing reports of hypersensitivity and anaphylaxis associated with acetaminophen, with infrequent reports of life-threatening anaphylaxis. Instruct patients to discontinue immediately and seek medical care if symptoms occur. Do not prescribe for patients with acetaminophen allergy.
- Spasm of the Sphincter of Oddi: Contraindicated in known or suspected gastrointestinal obstruction, including paralytic ileus. May cause spasm of the sphincter of Oddi, and opioids may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- Increased Risk of Seizures in Patients with Seizure Disorders: Codeine may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control.
- Withdrawal: Do not abruptly discontinue in a patient physically dependent on opioids. Rapid tapering in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain. Avoid mixed agonist/antagonist or partial agonist analgesics, which may reduce the analgesic effect and/or precipitate withdrawal symptoms. When discontinuing, gradually taper the dosage.
- Serotonin Syndrome: Concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome. Discontinue immediately if serotonin syndrome is suspected.
- Impaired Mental or Physical Abilities: May impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects and know how they will react.
Common Side Effects
The most frequently observed adverse reactions with codeine administration include drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, sweating, and constipation.
Pregnancy: Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Not recommended for use during or immediately prior to labor.
Lactation: Codeine and its active metabolite, morphine, are present in human milk. Excessive sedation, respiratory depression, and death have been reported in infants exposed to codeine via breast milk, and mothers who are ultra-rapid metabolizers may have higher levels of morphine in breast milk. Breastfeeding is not recommended during treatment.
The safety and effectiveness of acetaminophen and codeine phosphate tablets in pediatric patients below the age of 18 have not been established. Life-threatening respiratory depression and death have occurred in children who received codeine; in most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine. Contraindicated for all children younger than 12 years of age, and for postoperative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy. Avoid use in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks.